SCHEMBL408918

SCHEMBL408918

CCOC(=O)c1ccc(NC)c(N)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 3/20 0.67
ALOX15 P16050 1/20 0.64
PRKCI P41743 1/20 0.61
GAA P10253 2/20 0.56
LMNA P02545 2/20 0.56
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
MAOA P21397 1/20 0.56
CA1 P00915 3/20 0.53
CA2 P00918 3/20 0.53
CA12 O43570 2/20 0.53
CA7 P43166 2/20 0.53
CA9 Q16790 2/20 0.53
CA14 Q9ULX7 2/20 0.53
CDC25B P30305 2/20 0.49
KMT2A Q03164 1/20 0.49
ALDH1A1 P00352 3/20 0.49
MAPT P10636 2/20 0.49
KDM4E B2RXH2 2/20 0.49
THRB P10828 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2246699 0.88 PTGER4 (0.56) PTGER4ALOX15GAALMNACYP1A2
SCHEMBL14800323 0.86 PTGER4 (0.73) PTGER4ALOX15GAALMNACYP1A2
SCHEMBL19003293 0.85 CA12 (0.57) PTGER4ALOX15LMNACYP1A2CYP3A4
SCHEMBL6169580 0.85 PTGER4 (0.64) PTGER4ALOX15PRKCIGAALMNA
SCHEMBL4341372 0.84 ALOX15 (0.63) PTGER4ALOX15GAALMNACYP1A2
SCHEMBL6171237 0.84 PTGER4 (0.62) PTGER4ALOX15GAALMNACYP1A2
SCHEMBL542066 0.83 PRKCI (0.69) PTGER4ALOX15PRKCIGAALMNA
SCHEMBL11252923 0.83 PTGER4 (0.58) PTGER4ALOX15GAALMNACYP1A2
SCHEMBL27014428 0.83 PRKCI (0.54) PTGER4ALOX15PRKCIGAAALDH1A1
SCHEMBL8887638 0.82 PTGER4 (0.64) PTGER4ALOX15GAALMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4577537-A1 SUBSTITUTED BICYCLES AS HSET INHIBITORS Merck Patent GmbH (DE) 2025-07-02 EP disclosed
US-20240409533-A1 HMOX1 INDUCERS Astellas Engineered Small Molecules US, Incorporated 2024-12-12 US disclosed
US-12071433-B2 HMOX1 inducers Astellas Engineered Small Molecules US, Incorporated (US) 2024-08-27 US disclosed
WO-2024042007-A1 SUBSTITUTED BICYCLES AS HSET INHIBITORS MERCK PATENT GMBH (DE) 2024-02-29 WO disclosed
US-20240051952-A1 HMOX1 INDUCERS Astellas Engineered Small Molecules US, Incorporated 2024-02-15 US disclosed
US-20220177460-A1 HMOX1 INDUCERS Astellas Engineered Small Molecules US, Incorporated 2022-06-09 US disclosed
US-20220177460-A1 HMOX1 INDUCERS Astellas Engineered Small Molecules US, Incorporated 2022-06-09 US disclosed
EP-3952990-A1 HMOX1 INDUCERS Mitobridge, Inc. (US) 2022-02-16 EP disclosed
CN-113874074-A HMOX1 inducers 米托布里奇公司 2021-12-31 CN disclosed
WO-2020210339-A1 HMOX1 INDUCERS MITOBRIDGE, INC. (US) 2020-10-15 WO disclosed
US-20080220003-A1 C5a Receptor Antagonists JERINI AG (DE) 2008-09-11 US disclosed
US-20080220003-A1 C5a Receptor Antagonists JERINI AG (DE) 2008-09-11 US disclosed
US-20080220003-A1 C5a Receptor Antagonists JERINI AG (DE) 2008-09-11 US disclosed
CN-101189209-A C5a receptor antagonists JERINI AG (DE) 2008-05-28 CN disclosed
WO-2008048991-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2008-04-24 WO disclosed
EP-1885691-A1 C5A RECEPTOR ANTAGONISTS Jerini AG (DE) 2008-02-13 EP disclosed
WO-2008011130-A2 AMIDE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 WO disclosed
EP-1739078-A1 Antagonists of C5a-receptor Jerini AG (DE) 2007-01-03 EP disclosed
EP-1739078-A1 Antagonists of C5a-receptor Jerini AG (DE) 2007-01-03 EP disclosed
WO-2006128670-A1 C5A RECEPTOR ANTAGONISTS JERINI AG (DE) 2006-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240409533-A1 HMOX1 INDUCERS HMOX1, HMOX2, HMBS PTGER4 413/4885ALOX15 14/4885PRKCI 3241/4885
US-12071433-B2 HMOX1 inducers HMOX1, HMOX2, HMBS PTGER4 342/4885ALOX15 13/4885PRKCI 3252/4885
US-20240051952-A1 HMOX1 INDUCERS HMOX1, HMOX2, QSOX1 PTGER4 743/4885ALOX15 11/4885PRKCI 4716/4885
US-20220177460-A1 HMOX1 INDUCERS HMOX1, HMOX2, HMBS PTGER4 342/4885ALOX15 13/4885PRKCI 3252/4885
US-20080220003-A1 C5a Receptor Antagonists C3AR1, C5AR2, C5AR1 PTGER4 1141/4885ALOX15 753/4885PRKCI 4733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.